

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Zhou Jing</u> (Last) (First) (Middle) C/O ISOPLEXIS CORPORATION 35 NE INDUSTRIAL RD (Street) BRANFORD CT 06405 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/07/2021	3. Issuer Name and Ticker or Trading Symbol <u>IsoPlexis Corp [ISO]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Scientific Officer	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	10/28/2025	Common Stock	8,000 ⁽¹⁾	0.2788	D	
Stock Option (right to buy)	(2)	12/31/2025	Common Stock	1,600 ⁽²⁾	0.2788	D	
Stock Option (right to buy)	(3)	01/30/2027	Common Stock	4,000 ⁽³⁾	0.4775	D	
Stock Option (right to buy)	(4)	10/24/2027	Common Stock	22,000 ⁽⁴⁾	0.7263	D	
Stock Option (right to buy)	(5)	12/13/2028	Common Stock	8,000 ⁽⁵⁾	0.9625	D	
Stock Option (right to buy)	(6)	12/03/2029	Common Stock	30,000 ⁽⁶⁾	1.0275	D	
Stock Option (right to buy)	(7)	12/14/2030	Common Stock	12,000 ⁽⁷⁾	1.83	D	
Stock Option (right to buy)	(8)	06/07/2031	Common Stock	100,000 ⁽⁸⁾	4.81	D	

Explanation of Responses:

- Represents 8,000 time-vesting options. Time-vesting options were subject to a four-year time-based vesting schedule, with 25% vested on October 29, 2016 and the remainder vested in 36 equal installments every month thereafter.
- Represents 1,600 time-vesting options. Time-vesting options were subject to a four-year time-based vesting schedule, with 25% vested on January 1, 2017 and the remainder vested in 36 equal installments every month thereafter.
- Represents 4,000 time-vesting options. Time-vesting options were subject to a four-year time-based vesting schedule, with 25% vested on January 31, 2018 and the remainder vested in 36 equal installments every month thereafter.
- Represents 22,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vested on October 25, 2018 and the remainder vesting in 36 equal installments every month thereafter.
- Represents 8,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vested on December 5, 2019 and the remainder vesting in 36 equal installments every month thereafter.
- Represents 30,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vested on December 4, 2020 and the remainder vesting in 36 equal installments every month thereafter.
- Represents 12,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vesting on December 15, 2021 and the remainder vesting in 36 equal installments every month thereafter.
- Represents 100,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vesting on June 8, 2022 and the remainder vesting in 36 equal installments every month thereafter.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Shane Sevier, attorney-in-fact for Jing Zhou 10/07/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of John Strahley and Shane Sevier as the undersigned's true and lawful attorneys-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as a reporting person pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder of IsoPlexis Corporation (the "Company"), Forms 3, 4 and 5, including any amendments thereto, in accordance with Section 16(a) of the Exchange Act;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto and timely file such form with the United States Securities and Exchange Commission and the applicable stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of any of such attorneys-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any of such attorneys-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as any of such attorneys-in-fact may approve in the discretion of any of such attorneys-in-fact.

The undersigned hereby grants to each such attorney-in-fact full power and authority to act separately and to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that any of such attorneys-in-fact, or the substitute or substitutes of any of such attorneys-in-fact, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this July 26, 2021.

/s/ Jing Zhou
Name: Jing Zhou